[ad_1]
Original title: Volunteers have adverse reactions to suspend the trial of the new Oxford coronavirus vaccine
Due to an unexplained adverse reaction in a volunteer, the new Oxford coronavirus vaccine that has entered the final clinical trial will be discontinued. Among the many vaccines in development around the world, the vaccine developed jointly by the University of Oxford and the pharmaceutical company AstraZeneca has high hopes.
In recent weeks, Oxford Vaccine has entered the third phase of testing, with approximately 30,000 participants in the United States, Great Britain, Brazil and South Africa. According to the New York Times, a volunteer was diagnosed with transverse myelitis in a test in the UK, which may be caused by a viral infection. However, the cause of the disease has not been determined if it has any connection to the vaccine, and an independent investigation will now be conducted.
This is the second suspension of the vaccine trial since it entered clinical trials in April. A spokesperson for the University of Oxford said: “In large-scale trials, diseases do occasionally occur, but they must be independently monitored for verification.” All international vaccination sites are now on file before the medical regulatory agency makes the final decision to restart the trial.
According to the WHO, there are currently about 180 vaccines in development worldwide, but clinical trials have not yet been completed. The Oxford vaccine was one of the first vaccines to undergo clinical trials. The research team used a vaccine technology previously developed for SARS and began its first trial in 1,000 people in April. The results showed promise and safety, and the volunteers would develop antibodies after vaccination.
Kate Bingham, chair of the UK Vaccine Task Force, has expressed “confidence” that a vaccine will be found before the end of this year. She said: “What we will get is a vaccine that can reduce the severity of symptoms.” People no longer die from the new coronavirus and become ill with flu-like illnesses.
Effective vaccines must be carried out with extreme caution in clinical trials. Sir Patrick Vallance, the UK’s chief scientific adviser, told a press conference in Downing Street on the 9th that the discovery of a vaccine could take four months. Possibility of vaccination. British Health Secretary Matt Hancock admitted in an interview on Monday that the Oxford vaccine will not be available this year: “The best scenario is this year (the launch of the vaccine), but I think it is more likely to be early in the year. next year”. He said the British government has ordered many different types of vaccines and hopes that effective vaccines can be promoted in the UK as soon as possible.
So far, AstraZeneca has entered into an agreement with the Inclusive Vaccine Alliance (IVA), Epidemic Preparedness Innovation Alliance (CEPI), Global Vaccine Immunization Alliance (GAVI), and Serum Institute of India to provide over 2 billion promise of a vaccine.
